Global Hirudin

Hirudin Comprehensive Study by Type (Natural Hirudin, Recombinant Hirudin), Disease Indication (Heparin-Induced Thrombocytopenia, Unstable Angina, Tumors, Others) Players and Region - Global Market Outlook to 2027

Hirudin Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hirudin
The most significant and extensively researched active constituent, 65–66 amino acids from the tiny molecules of protein, has been isolated together with leech and salivary glands (peptide). The most natural thrombin-specific inhibitor to date, hirudin has a substantial inhibitory impact on thrombin. Hirudin is an efficient anticoagulant, antithrombotic, and can prevent thrombin-catalyzed activation of coagulation factors and platelet responses as well as the further development of the blood stasis phenomenon, according to animal research and clinical trials. Additionally, it prevented thrombin from stimulating endothelial cells or causing fibroblasts to proliferate.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hirudin market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer, Inc. (United States), Bayer Healthcare AG (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Abbott India Limited (India), GlaxoSmithKline Plc. (United Kingdom), Sanofi S.A. (France), Boehringer Ingelheim (Germany), Aspen Holdings (South Africa), Bristol-Myers Squibb Company (United States), Mitsubishi Tanabe Pharma Corporation (Japan) and Eisai Inc. (Japan) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Hirudin market by Type (Natural Hirudin and Recombinant Hirudin) and Region.



On the basis of geography, the market of Hirudin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Indication, the sub-segment i.e. Heparin-Induced Thrombocytopenia will boost the Hirudin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Hirudin Market Dynamics:
AttributesDetails
Growth Drivers
  • Rising Number of Patients Suffering From Trauma
  • Increasing Number of Thrombin Based Diseases
Restraints
  • Complete Dependence on Renal Function for Elimination
  • Predominant Renal Excretion and Immunogenicity, Have Been Overcome Through Development Of The Hirudin Analogue, Bivalirudin
Gaps & Opportunities
  • Growing Number of Healthcare Facilities in Emerging Economies


Market Leaders and their expansionary development strategies
In 2022, Eisai Co., Ltd. announced that Eisai has signed the Kigali Declaration made public at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) held on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the eradication of NTDs in order to achieve a road map for NTDs 2021–2030 launched by the World Health Organization (WHO). Based on the philosophy of human health care (hhc), Eisai has identified the eradication of NTDs as a key area of attention and seeks to advance social welfare by reducing health disparities.
In 2022, Lecanemab is an investigational anti-amyloid beta (A) protofibril antibody for the treatment of mild cognitive impairment (MCI) caused by Alzheimer's disease (AD) and mild AD (collectively known as early AD), with confirmed amyloid pathology in the brain. Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA the Prescription Drug User Fee Act (PDUFA) action deadline for Eisai's application, which was finished in early May 2022, is January 6, 2023.
The Food and Drug Regulations require anyone intending to sell or distribute these products in Canada to obtain market authorization. The Biologics and Genetic Therapies Directorate (BGTD) is the section of Health Canada that is responsible for the regulatory oversight of these products. Sponsors are encouraged to set up a pre-submission meeting with BGTD to discuss regulatory requirements for obtaining a market authorization medicinal maggots or medicinal leeches.
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Natural Hirudin
  • Recombinant Hirudin
By Disease Indication
  • Heparin-Induced Thrombocytopenia
  • Unstable Angina
  • Tumors
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Patients Suffering From Trauma
      • 3.2.2. Increasing Number of Thrombin Based Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hirudin, by Type, Disease Indication and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Hirudin (Value)
      • 5.2.1. Global Hirudin by: Type (Value)
        • 5.2.1.1. Natural Hirudin
        • 5.2.1.2. Recombinant Hirudin
      • 5.2.2. Global Hirudin by: Disease Indication (Value)
        • 5.2.2.1. Heparin-Induced Thrombocytopenia
        • 5.2.2.2. Unstable Angina
        • 5.2.2.3. Tumors
        • 5.2.2.4. Others
      • 5.2.3. Global Hirudin Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Hirudin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer Healthcare AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott India Limited (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Boehringer Ingelheim (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Aspen Holdings (South Africa)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bristol-Myers Squibb Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Eisai Inc. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Hirudin Sale, by Type, Disease Indication and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Hirudin (Value)
      • 7.2.1. Global Hirudin by: Type (Value)
        • 7.2.1.1. Natural Hirudin
        • 7.2.1.2. Recombinant Hirudin
      • 7.2.2. Global Hirudin by: Disease Indication (Value)
        • 7.2.2.1. Heparin-Induced Thrombocytopenia
        • 7.2.2.2. Unstable Angina
        • 7.2.2.3. Tumors
        • 7.2.2.4. Others
      • 7.2.3. Global Hirudin Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hirudin: by Type(USD Million)
  • Table 2. Hirudin Natural Hirudin , by Region USD Million (2016-2021)
  • Table 3. Hirudin Recombinant Hirudin , by Region USD Million (2016-2021)
  • Table 4. Hirudin: by Disease Indication(USD Million)
  • Table 5. Hirudin Heparin-Induced Thrombocytopenia , by Region USD Million (2016-2021)
  • Table 6. Hirudin Unstable Angina , by Region USD Million (2016-2021)
  • Table 7. Hirudin Tumors , by Region USD Million (2016-2021)
  • Table 8. Hirudin Others , by Region USD Million (2016-2021)
  • Table 9. South America Hirudin, by Country USD Million (2016-2021)
  • Table 10. South America Hirudin, by Type USD Million (2016-2021)
  • Table 11. South America Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 12. Brazil Hirudin, by Type USD Million (2016-2021)
  • Table 13. Brazil Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 14. Argentina Hirudin, by Type USD Million (2016-2021)
  • Table 15. Argentina Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 16. Rest of South America Hirudin, by Type USD Million (2016-2021)
  • Table 17. Rest of South America Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 18. Asia Pacific Hirudin, by Country USD Million (2016-2021)
  • Table 19. Asia Pacific Hirudin, by Type USD Million (2016-2021)
  • Table 20. Asia Pacific Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 21. China Hirudin, by Type USD Million (2016-2021)
  • Table 22. China Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 23. Japan Hirudin, by Type USD Million (2016-2021)
  • Table 24. Japan Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 25. India Hirudin, by Type USD Million (2016-2021)
  • Table 26. India Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 27. South Korea Hirudin, by Type USD Million (2016-2021)
  • Table 28. South Korea Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 29. Taiwan Hirudin, by Type USD Million (2016-2021)
  • Table 30. Taiwan Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 31. Australia Hirudin, by Type USD Million (2016-2021)
  • Table 32. Australia Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 33. Rest of Asia-Pacific Hirudin, by Type USD Million (2016-2021)
  • Table 34. Rest of Asia-Pacific Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 35. Europe Hirudin, by Country USD Million (2016-2021)
  • Table 36. Europe Hirudin, by Type USD Million (2016-2021)
  • Table 37. Europe Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 38. Germany Hirudin, by Type USD Million (2016-2021)
  • Table 39. Germany Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 40. France Hirudin, by Type USD Million (2016-2021)
  • Table 41. France Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 42. Italy Hirudin, by Type USD Million (2016-2021)
  • Table 43. Italy Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 44. United Kingdom Hirudin, by Type USD Million (2016-2021)
  • Table 45. United Kingdom Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 46. Netherlands Hirudin, by Type USD Million (2016-2021)
  • Table 47. Netherlands Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 48. Rest of Europe Hirudin, by Type USD Million (2016-2021)
  • Table 49. Rest of Europe Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 50. MEA Hirudin, by Country USD Million (2016-2021)
  • Table 51. MEA Hirudin, by Type USD Million (2016-2021)
  • Table 52. MEA Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 53. Middle East Hirudin, by Type USD Million (2016-2021)
  • Table 54. Middle East Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 55. Africa Hirudin, by Type USD Million (2016-2021)
  • Table 56. Africa Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 57. North America Hirudin, by Country USD Million (2016-2021)
  • Table 58. North America Hirudin, by Type USD Million (2016-2021)
  • Table 59. North America Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 60. United States Hirudin, by Type USD Million (2016-2021)
  • Table 61. United States Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 62. Canada Hirudin, by Type USD Million (2016-2021)
  • Table 63. Canada Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 64. Mexico Hirudin, by Type USD Million (2016-2021)
  • Table 65. Mexico Hirudin, by Disease Indication USD Million (2016-2021)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Hirudin: by Type(USD Million)
  • Table 78. Hirudin Natural Hirudin , by Region USD Million (2022-2027)
  • Table 79. Hirudin Recombinant Hirudin , by Region USD Million (2022-2027)
  • Table 80. Hirudin: by Disease Indication(USD Million)
  • Table 81. Hirudin Heparin-Induced Thrombocytopenia , by Region USD Million (2022-2027)
  • Table 82. Hirudin Unstable Angina , by Region USD Million (2022-2027)
  • Table 83. Hirudin Tumors , by Region USD Million (2022-2027)
  • Table 84. Hirudin Others , by Region USD Million (2022-2027)
  • Table 85. South America Hirudin, by Country USD Million (2022-2027)
  • Table 86. South America Hirudin, by Type USD Million (2022-2027)
  • Table 87. South America Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 88. Brazil Hirudin, by Type USD Million (2022-2027)
  • Table 89. Brazil Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 90. Argentina Hirudin, by Type USD Million (2022-2027)
  • Table 91. Argentina Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 92. Rest of South America Hirudin, by Type USD Million (2022-2027)
  • Table 93. Rest of South America Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 94. Asia Pacific Hirudin, by Country USD Million (2022-2027)
  • Table 95. Asia Pacific Hirudin, by Type USD Million (2022-2027)
  • Table 96. Asia Pacific Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 97. China Hirudin, by Type USD Million (2022-2027)
  • Table 98. China Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 99. Japan Hirudin, by Type USD Million (2022-2027)
  • Table 100. Japan Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 101. India Hirudin, by Type USD Million (2022-2027)
  • Table 102. India Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 103. South Korea Hirudin, by Type USD Million (2022-2027)
  • Table 104. South Korea Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 105. Taiwan Hirudin, by Type USD Million (2022-2027)
  • Table 106. Taiwan Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 107. Australia Hirudin, by Type USD Million (2022-2027)
  • Table 108. Australia Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 109. Rest of Asia-Pacific Hirudin, by Type USD Million (2022-2027)
  • Table 110. Rest of Asia-Pacific Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 111. Europe Hirudin, by Country USD Million (2022-2027)
  • Table 112. Europe Hirudin, by Type USD Million (2022-2027)
  • Table 113. Europe Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 114. Germany Hirudin, by Type USD Million (2022-2027)
  • Table 115. Germany Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 116. France Hirudin, by Type USD Million (2022-2027)
  • Table 117. France Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 118. Italy Hirudin, by Type USD Million (2022-2027)
  • Table 119. Italy Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 120. United Kingdom Hirudin, by Type USD Million (2022-2027)
  • Table 121. United Kingdom Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 122. Netherlands Hirudin, by Type USD Million (2022-2027)
  • Table 123. Netherlands Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 124. Rest of Europe Hirudin, by Type USD Million (2022-2027)
  • Table 125. Rest of Europe Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 126. MEA Hirudin, by Country USD Million (2022-2027)
  • Table 127. MEA Hirudin, by Type USD Million (2022-2027)
  • Table 128. MEA Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 129. Middle East Hirudin, by Type USD Million (2022-2027)
  • Table 130. Middle East Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 131. Africa Hirudin, by Type USD Million (2022-2027)
  • Table 132. Africa Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 133. North America Hirudin, by Country USD Million (2022-2027)
  • Table 134. North America Hirudin, by Type USD Million (2022-2027)
  • Table 135. North America Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 136. United States Hirudin, by Type USD Million (2022-2027)
  • Table 137. United States Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 138. Canada Hirudin, by Type USD Million (2022-2027)
  • Table 139. Canada Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 140. Mexico Hirudin, by Type USD Million (2022-2027)
  • Table 141. Mexico Hirudin, by Disease Indication USD Million (2022-2027)
  • Table 142. Research Programs/Design for This Report
  • Table 143. Key Data Information from Secondary Sources
  • Table 144. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hirudin: by Type USD Million (2016-2021)
  • Figure 5. Global Hirudin: by Disease Indication USD Million (2016-2021)
  • Figure 6. South America Hirudin Share (%), by Country
  • Figure 7. Asia Pacific Hirudin Share (%), by Country
  • Figure 8. Europe Hirudin Share (%), by Country
  • Figure 9. MEA Hirudin Share (%), by Country
  • Figure 10. North America Hirudin Share (%), by Country
  • Figure 11. Global Hirudin share by Players 2021 (%)
  • Figure 12. Global Hirudin share by Players (Top 3) 2021(%)
  • Figure 13. Global Hirudin share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Pfizer, Inc. (United States) Revenue: by Geography 2021
  • Figure 17. Bayer Healthcare AG (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Bayer Healthcare AG (Germany) Revenue: by Geography 2021
  • Figure 19. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 20. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2021
  • Figure 21. Abbott India Limited (India) Revenue, Net Income and Gross profit
  • Figure 22. Abbott India Limited (India) Revenue: by Geography 2021
  • Figure 23. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2021
  • Figure 25. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi S.A. (France) Revenue: by Geography 2021
  • Figure 27. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim (Germany) Revenue: by Geography 2021
  • Figure 29. Aspen Holdings (South Africa) Revenue, Net Income and Gross profit
  • Figure 30. Aspen Holdings (South Africa) Revenue: by Geography 2021
  • Figure 31. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2021
  • Figure 33. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2021
  • Figure 35. Eisai Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Eisai Inc. (Japan) Revenue: by Geography 2021
  • Figure 37. Global Hirudin: by Type USD Million (2022-2027)
  • Figure 38. Global Hirudin: by Disease Indication USD Million (2022-2027)
  • Figure 39. South America Hirudin Share (%), by Country
  • Figure 40. Asia Pacific Hirudin Share (%), by Country
  • Figure 41. Europe Hirudin Share (%), by Country
  • Figure 42. MEA Hirudin Share (%), by Country
  • Figure 43. North America Hirudin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer, Inc. (United States)
  • Bayer Healthcare AG (Germany)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Abbott India Limited (India)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Sanofi S.A. (France)
  • Boehringer Ingelheim (Germany)
  • Aspen Holdings (South Africa)
  • Bristol-Myers Squibb Company (United States)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Eisai Inc. (Japan)
Select User Access Type

Key Highlights of Report


Aug 2022 201 Pages 91 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hirudin Quantitative research analysis
Global Hirudin Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer, Inc. (United States), Bayer Healthcare AG (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Abbott India Limited (India), GlaxoSmithKline Plc. (United Kingdom), Sanofi S.A. (France), Boehringer Ingelheim (Germany), Aspen Holdings (South Africa), Bristol-Myers Squibb Company (United States), Mitsubishi Tanabe Pharma Corporation (Japan) and Eisai Inc. (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Hirudin Market during projected period 2021-2027.
The Hirudin market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hirudin Report?

Have a Query? Click Here

Other Related Reports

Prednisolone Acetate Comprehensive Study by Type (Prednisolone Acetate Tablet, Prednisolone Acetate Liquid, Prednisolone Acetate Emulsifiable Paste), Application (Hypersensitivity Disease, Autoimmune...
$ 3450
Sacral Nerve Stimulation Comprehensive Study by Type (Implantable, External), Application (Urinary & Fecal Incontinence, Urge Incontinence, Chronic Anal Fissure, Others), End User (Hospitals, Ambulat...
$ 3350
Scleroderma Diagnostics and Therapeutics Comprehensive Study by Application (Hospitals, Clinics), Diagnostics (Antibodies Tests/Blood Tests, Capillaroscopy, Cardiac Diagnosis, Gastrointestinal Diagno...
$ 3750
Renal Anemia Therapeutics Comprehensive Study by Type (DS-1093, EPO-018B, FG-2216, JTZ-951, MDGN-201), Application (Hospital, Research Center, Clinic), Mode of Administration (Oral, Parenteral) Playe...
$ 3500
Antihemophilic Factor Comprehensive Study by Type (Plasma Derived, Plasma Derived/VWF Complex, Recombinant Antihemophilic Factor), Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmac...
$ 3350
Sicca Syndrome Drug Comprehensive Study by Type (BMS-986142, Belimumab, Coversin, Filgotinib, LY-3090106, Others), Application (Hospital, Clinic, Others), Sales Channels (Online Sales Channel {Compan...
$ 3750